NCT01975480

Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities

Efficacy of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment on Prefrontality in Patients With Generalized Anxiety Disorder (GAD) and Other Comorbidities

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: START Clinic for Mood and Anxiety Disorders · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label flexible-dose pilot study evaluating the efficacy, safety, and tolerability of Pristiq (desvenlafaxine) in outpatient subjects diagnosed with Generalized Anxiety Disorder (GAD) with or without comorbidities that are secondary to the GAD. Primary trial objective is to evaluate the efficacy of Pristiq (desvenlafaxine) SNRI treatment 50 to 100 mg once daily in the treatment of GAD with or without comorbidities. Secondary trial objective is to determine whether or not treatment outcome in GAD is related to changes in cortical prefrontal activity of norepinephrine.

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Desvenlafaxine

Timeline

• Start date: 2013-01-01
• Primary completion: 2020-04-15
• Completion: 2020-05-01
• First posted: 2013-11-04
• Last updated: 2020-10-23

Locations

1 site across 1 country: Canada